DB05505InvestigationalSmall molecule
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan,... In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma.
- Mechanism
- Curator reviewed
NM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
- Primary indication
- Investigated for use/treatment in peripheral vascular disease.Curator reviewed
- Code names
- NM-702
Resolves to
Compound
Targets
What you can answer from here — as of April 02, 2025
Which drugs share a target with NM-702, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account